



Published in final edited form as:

*Breast Cancer Res Treat.* 2008 May ; 109(1): 123–139.

## Epidemiology of basal-like breast cancer

**Robert C. Millikan<sup>1,2</sup>, Beth Newman<sup>3</sup>, Chiu-Kit Tse<sup>1</sup>, Patricia G. Moorman<sup>4</sup>, Kathleen Conway<sup>1,2</sup>, Lisa V. Smith<sup>5,6</sup>, Miriam H. Labbok<sup>7</sup>, Joseph Geradts<sup>8</sup>, Jeannette T. Bensen<sup>1,2</sup>, Susan Jackson<sup>1,2</sup>, Sarah Nyante<sup>1</sup>, Chad Livasy<sup>9</sup>, Lisa Carey<sup>10</sup>, H. Shelton Earp<sup>2</sup>, and Charles M. Perou<sup>2,11</sup>**

<sup>1</sup> *Department of Epidemiology, CB #7435, School of Public Health, University of North Carolina, Chapel Hill, NC 27599-7435, USA*

<sup>2</sup> *Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina, Chapel Hill, NC, USA*

<sup>3</sup> *School of Public Health, Queensland University of Technology, Kelvin Grove, Queensland, Australia*

<sup>4</sup> *Department of Community and Family Medicine, School of Medicine, Duke University, Durham, NC, USA*

<sup>5</sup> *Division of Chronic Disease and Injury Prevention, Department of Public Health, Los Angeles County, Los Angeles, CA, USA*

<sup>6</sup> *Department of Epidemiology, School of Public Health, University of California, Los Angeles, CA, USA*

<sup>7</sup> *Center for Infant and Young Child Feeding and Care, Department of Maternal and Child Health, School of Public Health, University of North Carolina, Chapel Hill, NC, USA*

<sup>8</sup> *Department of Pathology, School of Medicine, Duke University, Durham, NC, USA*

<sup>9</sup> *Department of Pathology and Lab Medicine, University of North Carolina, Chapel Hill, NC, USA*

<sup>10</sup> *Department of Oncology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA*

<sup>11</sup> *Department of Genetics, University of North Carolina, Chapel Hill, NC, USA*

### Abstract

Risk factors for the newly identified “intrinsic” breast cancer subtypes (luminal A, luminal B, basal-like and human epidermal growth factor receptor 2-positive/estrogen receptor-negative) were determined in the Carolina Breast Cancer Study, a population-based, case–control study of African-American and white women. Immunohistochemical markers were used to subtype 1,424 cases of invasive and *in situ* breast cancer, and case subtypes were compared to 2,022 controls. Luminal A, the most common subtype, exhibited risk factors typically reported for breast cancer in previous studies, including inverse associations for increased parity and younger age at first full-term pregnancy. Basal-like cases exhibited several associations that were opposite to those observed for luminal A, including increased risk for parity and younger age at first term full-term pregnancy. Longer duration breastfeeding, increasing number of children breastfed, and increasing number of months breastfeeding per child were each associated with reduced risk of basal-like breast cancer, but not luminal A. Women with multiple live births who did not breastfeed and women who used medications to suppress lactation were at increased risk of basal-like, but not luminal A, breast cancer. Elevated waist-hip ratio was associated with increased risk of luminal A in postmenopausal women, and increased risk of basal-like breast cancer in pre- and postmenopausal women. The prevalence of basal-like breast cancer was highest among premenopausal African-American women, who also showed the highest prevalence of basal-like risk factors. Among younger African-American women,

we estimate that up to 68% of basal-like breast cancer could be prevented by promoting breastfeeding and reducing abdominal adiposity.

## Keywords

Breast cancer subtypes; molecular epidemiology

---

## Introduction

Almost two decades ago, Wetzels et al. [1] used immunohistochemical markers to identify a subset of breast tumors that exhibited a “basal cell phenotype,” in that the tumors expressed cytokeratins normally found only in the cell layer lying closest to the basement membrane of the mammary gland epithelium. Perou and colleagues [2–4] further characterized “basal-like” breast cancer as one of five principal subtypes identified in a supervised gene expression analysis of breast tumors. The “intrinsic” subtypes consisted of estrogen receptor (ER)-positive (luminal) tumors, two separate groups of ER-negative tumors [basal-like and human epidermal growth factor receptor 2 (HER2)-positive] and a group with a pattern resembling normal breast [2,3]. Luminal tumors stained for cytokeratins normally expressed in the upper, more differentiated breast epithelial layer (i.e., keratins 8/18), while basal-like tumors expressed cytokeratin 5/6. Luminal tumors were further subdivided into luminal A (ER-positive, HER2-negative) and luminal B (ER-positive, HER2-positive). The “intrinsic” subtypes have been reproduced across a variety of microarray platforms [5,6] and validated in numerous patient datasets from around the world [7,8]. The “intrinsic” classification system showed significant agreement in predicting clinical outcomes when compared with three other gene-expression based classification schemes, suggesting that these profiling methods identify distinct, stable biologic properties of breast tumors [9].

To investigate the prevalence of “intrinsic” subtypes in large, population-based datasets where fresh tumor tissue was not available, immunohistochemistry (IHC) surrogate markers were developed that could be applied to formalin-fixed, paraffin-embedded tumor blocks [10]. We applied these IHC markers to tumor blocks collected as part of the Carolina Breast Cancer Study (CBCS), a population-based, case-control conducted among African-American and white women in North Carolina. The “intrinsic” subtypes were observed in invasive [11] as well as *in situ* [12] breast cancer. The presence of the basal-like subtype in *in situ* breast cancer suggests that this phenotype is established early in breast carcinogenesis, and could therefore reflect a distinct pathway for disease etiology. In the CBCS, the prevalence of basal-like breast cancer was highest among premenopausal African-American women, while luminal A was most common among postmenopausal white women [11].

In the present analysis, we used exposure information collected from the CBCS to identify risk factors for the five breast cancer subtypes, with an emphasis on comparing two of the most distinct subtypes, namely luminal A and basal-like. We estimated the prevalence of risk factors for basal-like breast cancer among controls in the CBCS dataset, and estimated population attributable fractions that may be useful for prioritizing interventions to reduce the incidence of basal-like breast cancer, particularly among younger African-American women.

## Methods

### Study design and sampling

The CBCS is a population-based, case-control study conducted in 24 counties of North Carolina that combines molecular biology and population-based epidemiology to understand the causes of breast cancer [13]. Cases were identified from the North Carolina Central Cancer

Registry, and controls were identified using Drivers' License and Medicare beneficiary lists [14]. Participants provided informed consent using documents approved by the Institutional Review Board at the University of North Carolina School of Medicine. Women with invasive breast cancer and population controls were enrolled during Phase 1 (1993–1996) and Phase 2 (1996–2001). Randomized recruitment was used to oversample younger and African-American cases so that sample sizes would be sufficient for separate analyses [15]. Women with carcinoma *in situ* (CIS) and population controls were enrolled only during the latter time period (1996–2001). All cases of CIS [including ductal carcinoma *in situ* (DCIS), DCIS with microinvasion to a depth of 2 mm, and lobular carcinoma *in situ* (LCIS)] were eligible. Controls were frequency matched to cases by age and race using randomized recruitment [15]. Participants ranged in age from 20 to 74 years. Contact, cooperation, and overall response rates have previously been published for each phase of the study [16]. The portion of the CBCS designed to evaluate invasive breast cancer included 1,803 cases (787 African-American, 1,016 white) and 1,564 controls (718 African-American, 846 white), with overall response rates of 76% for cases and 55% for controls. The portion of the CBCS that evaluated carcinoma *in situ* (CIS) comprised 508 cases (107 African-American, 401 white) and 458 controls (70 African-American, 388 white), with overall responses rates of 83% for cases and 65% for controls.

### In-person interviews and body size measurements

In-person interviews were conducted for cases and controls by trained nurses. Participants were asked detailed information about family history of cancer and reproductive history, including age at onset of regular menstruation, age at first full-term pregnancy (AFFTP) and number of children, breastfeeding and onset of menopause. Women were asked to compare their weight to their peers during fifth grade, and to provide information on recreational physical activity, household or farm chores, and walking or biking to school at age 12, and frequency of recreational physical activity as an adult. Additional information was obtained on environmental exposures (smoking, alcohol use), hormone use (oral contraceptives; hormone replacement therapy, HRT), and socioeconomic status (income, education, occupational history) [17–20]. Participants were also asked about prior medical conditions, including diabetes mellitus.

Measurements were taken of waist circumference, hip circumference and body weight at the time of interview.

### Tumor blocks and immunohistochemistry assays

Women with invasive and *in situ* breast cancer were asked for permission to obtain relevant medical records and pathology reports (to confirm eligibility) and access to tumor blocks (for centralized review, sectioning and immunohistochemistry assays) [21]. The distributions of breast cancer “intrinsic” subtypes was previously published for 496 cases from Phase 1 of the invasive portion [11] and 245 cases from the CIS portion [12]. For the present analysis, we added data from an additional 653 cases of invasive breast cancer from Phase 2 and 30 cases from the CIS study. The additional CIS cases included three women with DCIS, 17 with DCIS with microinvasion and 10 with LCIS that were not included in the previous analysis [12]. In total, this article therefore presents data from 1,424 cases (1,149 invasive and 275 *in situ*) with sufficient tissue for IHC analysis, comprising 62% (1,424/2,311) of enrolled CBCS cases. A comparison of cases with IHC marker data to those without yielded no statistically significant differences for age, menopausal status, family history of breast cancer, or other covariates, with the following exceptions: African Americans and patients with later stage at diagnosis were more highly represented in the IHC marker dataset compared to cases without marker data. African-American women in the CBCS tended to be diagnosed with later stage tumors

than white women, and tumors with adequate tissue for IHC assays tended to be slightly larger than tumors with insufficient tissue [11].

Tumor blocks were sectioned and stained for a panel of IHC markers at the Immunohistochemistry Core Laboratory, University of North Carolina (UNC). For invasive cases, ER and progesterone receptor (PR) status were abstracted from medical records for 80% of cases and determined using IHC assays performed at UNC for the remaining cases [22]. For *in situ* cases, ER status was determined using IHC. For all cases, IHC assays for HER2, HER1 (EGFR), and CK5/6 assays were conducted using assay procedures and cutpoints for positivity as previously described [11,12]. Subtype definitions for invasive cases were based upon five IHC markers: luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), basal-like (ER-, PR-, HER2-, HER1+ and/or CK5/6+), HER2+/ER- (ER-, PR-, HER2+) and unclassified (negative for all five markers). For *in situ* disease, four IHC markers were used: luminal A (ER+, HER2-), luminal B (ER+, HER2+), basal-like (ER-, HER2-, HER1+ and/or CK5/6+), HER2+/ER- (ER-, HER2+) and unclassified (negative for all four markers). PR status was not determined for *in situ* cases in order to preserve tissue sections. For *in situ* breast cancer, PR+ tumors are almost always ER+. In one recent study of DCIS, ER and PR status were strongly correlated ( $P < 0.001$ ), and fewer than 1% of tumors were ER- and PR+ [23].

### Statistical analysis

Race was categorized based upon self-report as African-American or white. The latter category included fewer than 2% of participants who listed their race as Native American, Asian, mixed or other race, while the remainder classified themselves as white. Menopausal status was determined using information from the interview. Women younger than 50 years were classified as postmenopausal if they had undergone natural menopause, bilateral oophorectomy, or irradiation to the ovaries, otherwise they were classified as premenopausal. For women aged 50 or older, menopausal status was assigned based upon cessation of menstruation.

Body mass index (BMI) was calculated as body weight (kg)/height (m)<sup>2</sup> and used as a measure of general adiposity. Categories for BMI were based upon National Heart, Lung, and Blood Institute (NHLBI) cutpoints (<25 normal or underweight, 25–29 overweight, ≥30 obese) [24]. Waist-hip ratio (WHR) was calculated as the ratio of waist to hip circumference (cm) and used as a measure of abdominal adiposity. Cutpoints for WHR were tertiles based upon the distribution in controls. Other covariates were defined as previously reported [14,17–20]. Briefly, women who had smoked at least 100 cigarettes in their lifetime, consumed any alcoholic beverages, or used oral contraceptives or HRT at any time were classified as “ever users.” Breastfeeding was categorized according to the total lifetime number of months of breastfeeding, the number of children breastfed, months of breastfeeding per child, and use of medications to suppress lactation. The average number of children breastfed and months breastfeeding per child were calculated for each woman based upon information obtained for each live birth. Women were also asked about lactation failure or other problems with breastfeeding.

The prevalence of breast cancer subtypes (among cases) and participant characteristics and risk factors (cases and controls) were adjusted for the sampling probabilities used to select eligible participants, as implemented in SUDAAN version 9.0.1 (Research Triangle Institute, Research Triangle Park, NC). Distributions across categories were compared using adjusted Chi square tests.

Unconditional logistic regression was used to calculate odds ratios (ORs) as a measure of association, as implemented in SAS version 8.2 (SAS Institute, Cary NC). Odds ratios were

calculated among cases only using luminal A, the most common subtype, as the comparison group. Case-only analyses using disease subtypes are a useful exploratory tool to uncover etiologic heterogeneity [25]. In the present application, the case-only OR estimates the relative strength of association between a risk factor and a given disease subtype (basal-like, luminal B, HER2+/ER-, or unclassified) versus the same exposure and luminal A (ratio of ORs). Case-only ORs were adjusted for age and/or race, and supplemental analyses were conducted adjusting for American Joint Committee on Cancer (AJCC) stage at diagnosis (stage 0 or *in situ*, 1, 2, 3 + 4).

Odds ratios comparing cases and controls were calculated to further investigate the etiology of the five subtypes (estimate risk ratios), with each subtype separately compared to all controls ( $N = 2,022$ ). Potential confounders were selected based upon prior knowledge, directed acyclic graphs (DAGs) [26,27] and by selecting variables that resulted in a 10% or greater change in the beta estimate for the exposures of interest. Prior knowledge dictated that ORs for waist circumference and WHR be adjusted for BMI [28,29]. Odds ratios for BMI and WHR were also calculated after stratifying on menopausal status, and postmenopausal women were further stratified based upon use of HRT [28]. DAGs dictated that we not adjust parity and lactation ORs for WHR or BMI, since the latter variables could lie on a causal pathway between the exposures of interest and breast cancer. The list of exposures of interest and potential confounders included family history, reproductive history, measures of body size, weight gain, physical activity, environmental exposures, hormone use, and socioeconomic status (education and family income).

When the analysis was restricted to parous women, ORs for breastfeeding variables were attenuated slightly and estimates were less precise, therefore results are presented using the more stable referent category of nulliparous women. Odds ratios for lifetime duration of breastfeeding used a cutpoint of 4 months since no additional protective effects were observed for longer duration. Odds ratios for breastfeeding variables did not differ among women who reported having trouble breastfeeding or being unable to lactate. Odds ratios for reproductive and breastfeeding variables were similar (although less precise) after stratifying on race and menopausal status, and ORs did not differ substantially when CIS cases and controls were removed from the analysis.

To evaluate multiplicative interaction, likelihood ratio tests (LRTs) were used to calculate  $P$ -values comparing models with main effects to models with main effects plus relevant interaction term/s. Likelihood ratio tests were not significant for the interaction of the exposures of interest and race or menopausal status. In particular, for basal-like breast cancer, LRTs yielded non-significant results for the interaction of parity and race ( $P = 0.22$ ), parity and menopausal status ( $P = 0.46$ ), parity/breastfeeding composite variable and race ( $P = 0.32$ ), and parity/breastfeeding and menopausal status ( $P = 0.41$ ). Therefore, results are presented combining African and white women, and pre- and postmenopausal women. For BMI and WHR, ORs were similar after stratifying on race and LRTs were not significant.

Tests for trend were conducted by calculating  $P$ -values for the beta coefficient in logistic regression models with exposure coded as an ordinal variable. All statistical tests were two-sided with an alpha level of 0.05.

Population attributable fractions (PAFs) for basal-like breast cancer were estimated using the method of Bruzzi et al. [30]. PAFs combine information on the relative risk (estimated in the present study by the OR) and prevalence for a given exposure or group of exposures in the dataset of interest. The 95% CIs for PAFs were calculated using the bootstrap method described by Rockhill et al. [31]. Briefly, 1,000 random samples, with replacement, stratified on case-control status were repeatedly drawn from the original dataset. PAFs were calculated for each



random sample, resulting in 1,000 PAFs, and the 2.5th and 97.5th percentiles of the frequency distribution served as the approximate 95% CI for the original PAF estimate.

## Results

### Distribution of breast cancer subtypes

The distribution of “intrinsic” breast cancer subtypes in the combined CBCS datasets (invasive and *in situ*) is presented in Table 1. Among the 1,424 cases with IHC marker data, 796 (56%) were classified as luminal A, 225 (16%) were basal-like, 116 (8%) were HER2+/ER-, 137 (10%) were luminal B, and the remaining 150 cases (10%) were unclassified. For *in situ* tumors, all cases of LCIS were classified as luminal A, while DCIS with microinvasion was divided among all five subtypes, similar to the distributions reported previously for pure DCIS [12]. The distribution of “intrinsic” subtypes differed significantly by race and menopausal status ( $P < 0.0001$ ) (Table 1). Postmenopausal white women showed the highest prevalence of luminal A, while premenopausal African-American women exhibited the highest prevalence of basal-like breast cancer.

### Case-only odds ratios

Case-only ORs comparing each subtype to luminal A are presented in Table 2, and were minimally adjusted for age and/or race. Compared to luminal A, basal-like cases tended to be younger, African-American, and have younger age at menarche, higher parity, younger age at first full-term pregnancy, shorter duration breastfeeding and higher BMI and WHR (especially among premenopausal women). HER2+/ER-, luminal B, and unclassified cases also tended to be younger than luminal A cases. HER2+/ER- cases were slightly more likely to be African-American but less likely to be premenopausal. Luminal B cases had older age at first full-term pregnancy, and were more likely to consume alcohol and use HRT, and less likely to be obese or have central distribution of fat. Unclassified cases were more likely to be African-American, and had younger age at menarche and increased parity compared with luminal A. There were no significant interactions between race and menopausal status for each of the four subtypes compared to luminal A. Odds ratios did not differ after adjustment for stage at diagnosis (data not shown).

### Case-control odds ratios

Odds ratios for luminal A cases versus controls, and basal-like cases versus controls, are presented in Table 3. Younger age at menarche was positively associated with basal-like, but not luminal A, breast cancer. Parity, regardless of the number of live births, and younger AFFTP (before 26 years) showed inverse associations with luminal A breast cancer. In contrast, significant, positive increases in risk of basal-like breast cancer were observed with increasing number of live births and younger age at first full-term pregnancy. Inverse associations were observed for breastfeeding and basal-like breast cancer, with significant trends for lifetime duration of lactation, number of children breastfed, and average number of months breastfeeding per child. Use of lactation suppressants was positively associated with basal-like but not luminal A breast cancer.

The composite variable “parity and lactation” exhibited a strong positive association for basal-like breast cancer among women who had 1–2 children and never breastfed, and a slightly stronger association for women with 3 or more children who never breastfed (Table 3). The composite variable “parity and AFFTP” showed stronger positive associations with basal-like breast cancer for parous women with AFFTP <26 than women with AFFTP of 26 or greater. In contrast, inverse associations with luminal A were observed for both composite variables. A composite variable that included parity, AFFTP and breastfeeding demonstrated that higher parity and lack of breastfeeding were the main contributors to increased risk of basal-like breast

cancer, with little additional contribution from younger AFFTP (data not shown). Among parous women, ORs for breastfeeding and AFFTP did not change after mutual adjustment, and there was no evidence for interaction between the two variables.

Additional analyses were conducted for timing of pregnancy and breast cancer subtypes. The average interval between pregnancies did not differ across the five breast cancer subtypes ( $P = 0.11$ ). The proportion of women with three or more pregnancies and at least one interval between pregnancies of a year or less was 21% for luminal A and 20% for basal-like cases. The proportion of women who were pregnant or diagnosed with breast cancer within 1 year of being pregnant did not differ across the five subtypes ( $P = 0.14$ ). However, time between last pregnancy and breast cancer diagnosis was longer for luminal A compared to the other case subtypes ( $P = 0.002$ ), which may be attributable to the fact that luminal A cases were older relative to the other groups.

For BMI, ORs were slightly inverse or close to the null for both luminal A and basal-like breast cancer (Table 3). Among postmenopausal women, increasing tertiles of WHR were positively associated with luminal A, however, WHR showed stronger positive associations with basal-like breast cancer for pre- and postmenopausal women. Among postmenopausal women, results for BMI and WHR were similar after stratification on use of HRT (data not shown).

Among cases and controls in the CBCS, elevated BMI, WHR, and waist circumference were positively associated with history of diabetes mellitus (data not shown). However, the prevalence of diabetes mellitus did not differ across the five breast cancer subtypes ( $P = 0.59$ ). Women who reported a gain in adiposity since childhood had increased risk of basal-like breast cancer, while women who decreased in adiposity were at reduced risk. Specifically, women with an elevated WHR measured at interview ( $\geq 0.77$ ) who reported being thinner than their peers in fifth grade had elevated risk of basal-like breast cancer (adjusted OR = 2.2, 95% CI 1.5–3.4), relative to women with lower WHR who were thinner than their peers in fifth grade. In contrast, women who reported being heavier than their peers in fifth grade and whose current WHR was low exhibited an inverse association with basal-like breast cancer (OR = 0.5, 95% CI 0.2–1.4). The comparable ORs were close to the null for luminal A breast cancer. The proportion of women reporting gains in adiposity since fifth grade was higher among African-American controls (63%) compared to white controls (42%) ( $P = 0.0002$ ).

Case-control ORs for the luminal B, HER2+/ER- and unclassified subtypes were largely similar to luminal A, with the following exceptions. Luminal B cases showed a stronger positive association with alcohol use than the other subtypes (adjusted case-control OR = 1.7, 95% CI 1.1–2.7), and no association with elevated WHR. Whereas luminal A, basal-like and HER2+ subtypes showed weak inverse associations with postmenopausal HRT, the case-control OR for luminal B was slightly above the null (OR = 1.1, 95% CI 0.7–1.9).

### Prevalence of risk factors for basal-like breast cancer

The distribution of risk factors for basal-like breast cancer differed among the four race-menopausal status groups (Table 4). Prevalence estimates are based upon controls, and represent weighted estimates for women residing in the 24-county region of North Carolina sampled by the CBCS. Premenopausal African-American women showed the highest prevalence of menarche before age 13 years and never breastfeeding, and the lowest prevalence of lifetime breastfeeding of 4 months or longer,  $\geq 2$  children breastfed and  $\geq 4$  months breastfeeding per child.

Even stronger differences between African-American and white women emerged when we subdivided younger women into two age groups, less than age 40 and aged 40 to 50 (Table 5). Younger African-American women had a higher prevalence of each of the principal risk factors

for basal-like breast cancer: higher parity, lower breastfeeding, higher parity combined with lower breastfeeding, greater use of lactation suppressants, and elevated WHR. Among parous women, African Americans in each age group reported younger AFFTP, fewer children breastfed, and fewer months breastfeeding per child.

### Population attributable fractions

Population attributable fractions for basal-like breast cancer were estimated for the two most easily modified risk factors: breastfeeding (never versus ever) and elevated WHR ( $\geq 0.77$  vs.  $< 0.77$ ). For the entire study population, the PAF was 53% (95% CI 33.3–68.9). Among the four age-race groups, PAFs for basal-like breast cancer were 68% (95% CI 30.0–90.1) for premenopausal African-American women, 57% (–20.5 to 93.1) for postmenopausal African-American women, 37% (–15.1 to 68.4) for pre-menopausal white women, and 38% (–12.5 to 74.5) for postmenopausal African-American women. The PAF for a set of risk factors can be interpreted as the proportion of breast cancer that would be eliminated if the entire study population was moved from the exposed to the unexposed level for each of the relevant exposures.

### Discussion

In a population-based epidemiologic study of African-American and white women, we observed differing magnitudes of association for several breast cancer risk factors when we subdivided cases according to the “intrinsic” subtypes (luminal A, luminal B, basal-like, HER2 +/ER–and unclassified). Exploratory case-case comparisons were most striking for luminal A versus basal-like breast cancer, and analyses comparing cases and controls yielded several potential risk factors for basal-like cancer that differed in magnitude and direction in comparison with luminal A. Parity combined with lack of breastfeeding, early-onset menarche, younger AFFTP, use of lactation suppressants, elevated WHR and gain in adiposity since childhood were positively associated with basal-like breast cancer. Notably, each of these risk factors was more prevalent among younger African-American women, as represented by controls in the CBCS. The results suggest that a large part of the racial difference in the distribution of the “intrinsic” breast cancer subtypes may be attributable to differing distributions of specific risk factors related to reproductive history, breastfeeding, adiposity and weight gain.

In a recent article, Anderson et al. [32] examined incidence rates for breast tumors with poor prognostic features (ER and PR negative, tumor size greater than 2.0 cm, lymph node positive, high grade) compared to tumors with a more favorable prognosis (hormone receptor positive, size 2.0 cm or less, lymph node negative, low grade). Incidence rates were higher for poor prognosis tumors until ages 30–44, followed by a plateau at age 50 and a subsequent reduction, whereas incidence rates for more favorable prognosis tumors were higher in women aged 50 years and continued to rise as women grew older. The authors hypothesized that high- and low-risk breast tumors represent distinct subtypes of breast cancer with separate risk factor profiles and/or cell types of origin. In a similar vein, Bernards and Weinberg [33] cited biologic data to support a theory that breast cancer prognosis is “preordained by the spectrum of mutations that progenitor cells acquire relatively early in tumorigenesis; that is, some cancers start out on the wrong foot” [33: page 823]. Therefore, incidence rates and genetic data together support the idea that poor prognosis breast tumors in younger women have a different underlying etiology than more favorable breast cancers in older women. This hypothesis is especially relevant for younger African-American women, for whom breast cancer incidence remains high compared to white women [34] and mortality from hormone receptor negative, high grade breast cancer is a major public health problem [35–37].



Increased parity and younger AFFTP have been associated with increased risk of breast cancer among younger African-American women in several studies [38–40] including the CBCS [41], but not in others [42] (for review, see Swanson et al. [35]). We observed a statistically significant increase in risk of basal-like breast cancer with increasing number of children, a relationship that was not observed for luminal A breast cancer. The relationship between parity and basal-like breast cancer was not confined to younger women, and basal-like cases were no more likely to be diagnosed following a pregnancy than luminal A cases. Thus, the positive association between parity and basal-like breast cancer was not restricted to the well-documented short-term increase in risk of breast cancer following live birth [41,43]. Nor did the increase in risk appear to be attributable to younger age at menarche or younger AFFTP which have also been associated with increased risk of breast cancer in younger African-American women [35]. Rather, the increased risk for basal-like breast cancer with increasing parity appeared to be largely confined to women who did not breastfeed (Table 3). Furthermore, the effects of increased parity and lower breastfeeding, and the contrast between basal-like and luminal A breast cancer, were observed across all four age-race groups. In the case-only analysis comparing basal-like versus luminal A breast cancer, the OR for parity  $\geq 3$  and no breastfeeding (adjusted for age and race) was 1.9 (95% CI 1.1–3.4) for all women. In the four patient groups, ORs (adjusted for age) were 2.2 (95% CI 0.7–6.6) for pre-menopausal African-American women, 1.9 (95% CI 0.6–5.9) for postmenopausal African-American women, 1.8 (95% CI 0.5–7.0) for premenopausal white women, and 1.7 (95% CI 0.5–5.6) in postmenopausal white women.

The Collaborative Group on Hormonal Risk Factors in Breast Cancer [44] determined that breastfeeding exerts a protective effect on overall breast cancer risk beyond that of parity alone. Potential mechanisms include induction of terminal differentiation and/or removal of initiated breast epithelial cells, removal of estrogens via breast fluid, excretion of carcinogenic agents, delay in ovulation, and changes in breast pH [45]. Use of lactation suppressants has also been associated with increased breast cancer risk, although results were not consistent across studies [45]. Several lines of evidence suggest a link between basal-like breast cancer and lack of breastfeeding. Symmans et al. [46] found that overexpression of the basal-like marker, GABApi, was associated with younger age at diagnosis and shorter duration of breastfeeding among Hispanic breast cancer patients. *BRCA1*, but not *BRCA2*, mutation carriers show a high prevalence of basal-like breast cancer (for review, see Tischowitz and Foulkes [47]). In one study, *BRCA1* carriers who breastfed for 1 year or longer were less likely to develop breast cancer than mutation carriers who did not breastfeed; no effect of breastfeeding was seen for *BRCA2* carriers [48]. As suggested by Tischowitz and Foulkes [47], full-term pregnancy followed by failure to breastfeed or reduced duration of breastfeeding could result in retention of initiated progenitor cells that ultimately die or differentiate during lactation, and these retained cells could presumably develop into basal-like breast tumors. Pregnancy confers specific gene expression signatures on breast tissue and may effect the distribution and differentiation of potential breast cancer stem cells [49], but the effects of lactation on gene expression and the differentiation status of mammary epithelial cells are not well understood.

The other strong risk factor for basal-like breast cancer identified in the CBCS was WHR. Elevated WHR was associated with a strong increase in risk of basal-like breast cancer among pre- and postmenopausal women, and a more modest increase for luminal A among postmenopausal women. When the two components of WHR were examined separately, elevated waist circumference showed a strong positive association with basal-like breast cancer among pre- and postmenopausal women, while ORs for hip circumference were slightly inverse (data not shown). Waist circumference and WHR serve as surrogates for abdominal adiposity: waist circumference is correlated with the amount of visceral and subcutaneous fat, while WHR is used as an index of the relative accumulation of abdominal versus gluteal fat [28]. Previous epidemiologic studies have shown a consistent association between elevated

central adiposity and increased breast cancer risk in postmenopausal women [50], while results for premenopausal women have been less consistent [28,29]. Abdominal adiposity is correlated with hyperinsulinemia and insulin resistance among African-American and white women [51,52], and insulin resistance has been hypothesized to increase breast cancer risk in premenopausal women through increased mitotic activity and enhanced cell proliferation in breast epithelial tissue [28]. There are currently no biologic data linking insulin resistance with basal-like breast cancer, and our data do not support an association between prior history of diabetes mellitus and increased risk of basal-like disease. However, overexpression of the leptin receptor is found in breast tumors with high grade [53], a feature associated with basal-like breast cancer.

Our results combining recalled weight in fifth grade with measured WHR at the time of interview suggest that weight gain and/or gain in abdominal adiposity over a woman's lifetime may contribute to increased risk of basal-like breast cancer. Previous studies reported a stronger association between weight gain and risk of postmenopausal compared with premenopausal breast cancer [54,55]. Slattery et al. [56] found that weight gain since age 15 and elevated WHR were both associated with increased risk of ER-negative breast cancer. The latter results were presented combining pre- and postmenopausal women, and HER2 status was not included in tumor subtyping.

In addition to Slattery et al. [56], the work of other researchers suggests that risk factors for breast cancer differ depending upon hormone receptor status of the tumor [22,57–62]. Although differences were slight, the results suggest that traditional risk factors based upon reproductive history are associated with increased risk of hormone-receptor positive disease [63,64], which is consistent with our findings for the luminal A breast cancer subtype. Other studies stratified cases based upon HER2 positivity; but strong differences were not noted (for review, see Huang et al. [65]).

Previous studies reported a higher frequency of hormone-receptor negative breast cancer and later stage at diagnosis among African-American and other minority women compared with white women in the United States [37,60,61]. Recently, researchers at the California Cancer Registry found that breast cancer patients with the “triple negative” (ER-, PR-, HER2-) phenotype were more likely to be under age 40, African-American, or Hispanic [66]. “Triple negative” breast cancer was more frequent among women of lower socioeconomic status. The authors used the “triple negative” phenotype as a partial surrogate for basal-like breast cancer, since IHC data were limited to ER, PR and HER2 status. Individual-level data were not available on breast cancer risk factors, and socioeconomic status was assigned at the census block level using address at the time of diagnosis. In the CBCS, lower socioeconomic status (based upon income and education) was not associated with increased frequency of basal-like breast cancer. However, lower socioeconomic status was strongly associated with several risk factors for basal-like cancer, including lower breastfeeding ( $P < 0.0001$ ) and elevated WHR ( $P < 0.0001$ ). Future studies are needed to determine whether the increased prevalence of triple negative breast cancer found among Hispanic women in California may be attributable to reproductive history, breastfeeding, central adiposity and other basal-like risk factors.

Only one previous population-based study examined risk factors for breast cancer based upon the joint distribution of ER, PR, HER2, HER1, and CK5/6, the five IHC markers used to identify the “intrinsic” subtypes in the CBCS. Using data collected from a case-control study in Poland, Yang et al. [67] calculated ORs for each of the five breast cancer subtypes versus controls. Results were similar to the CBCS, in that luminal A and basal tumors showed distinct risk factor profiles, with luminal A showing associations typically described for breast cancer as a whole. The authors reported positive associations for younger age at menarche and parity with basal-like cancer, but breastfeeding was not addressed. An inverse association between

elevated BMI and luminal A breast cancer was observed among premenopausal women, but no association was seen for basal-like breast cancer, similar to our results. The authors did not examine WHR. Age at menarche and parity were associated with luminal A but not HER2+/ER- breast cancer. In the CBCS, case-control ORs for HER2+/ER- were almost identical to luminal A, with the exception of a slight inverse association for elevated WHR among postmenopausal women. Yang et al. [67] reported a stronger association with family history for basal-like breast cancer compared to the other subtypes. In our study, associations with family history were nearly identical across the five subtypes, with age and race-adjusted case-control ORs equal to 1.5 (95% CI 1.2–1.9) for luminal A and 1.7 (95% CI 1.1–2.5) for basal-like breast cancer. The only other epidemiologic study to examine risk factors for the “intrinsic” breast cancer subtypes was a population-based case series from Sweden [8] in which the authors subdivided cases based upon gene expression profiling. Current users of HRT were over-represented in the “normal-like” or “unclassified” breast tumor subtype. In the CBCS, the case-control OR for postmenopausal HRT and the unclassified subtype was 1.0 (95% CI 0.6–1.7).

A primary focus of the present analysis was to identify modifiable risk factors that could be targeted to reduce the risk of basal-like breast cancer, particularly among younger African-American women who have the highest incidence of this breast cancer subtype. Mortality rates are higher among younger African-American breast cancer patients, and the disparity in breast cancer outcomes has worsened over time [34]. Since basal-like breast cancer confers a poor prognosis [6, 11], understanding the etiology of this breast cancer subtype is an important public health problem. We estimated that approximately two-thirds (68%) of basal-like breast cancer in younger African-American women (and over half of the disease in the general population) could be prevented by interventions that increase breastfeeding and decrease abdominal adiposity.

There are a number of limitations to PAF estimates, since they are based upon very strong assumptions. First, PAFs estimate the proportion of disease that would be eliminated if the entire population was moved from the exposed to the unexposed level for each of the relevant risk factors, assuming that the exposures in question are causal. One or more of the associations observed in this article could have resulted from recall bias, confounding, or other sources of systematic error. However, it is unlikely that exposure misclassification would be differential by breast cancer subtype, and extensive analyses were conducted to address the possibility of confounding. Analyses of participants with and without IHC marker data, and previous analyses comparing participants and non-participants in the CBCS [68], suggest that selection bias is also unlikely. Data from subsequent population-based studies that utilize “intrinsic” subtypes will provide important information as to whether the associations observed in this article are causal. Second, the afore-mentioned PAF estimates assume that all women in the population are able to breastfeed children and reduce their WHR below 0.77. Clearly, not all women will have children, and there may be significant barriers to both breastfeeding and reducing abdominal adiposity. Third, the calculations assume independence of breastfeeding and WHR from other risk factors, such that the remaining risk factors for basal-like breast cancer are not changed by modifying the two exposures in question. Finally, PAFs should not be interpreted as the proportion of disease that can be “explained” by any specified group of risk factors. Since PAFs do not necessarily add up to 100%, it is possible that many additional exposures could contribute to the risk of basal-like disease. Despite these limitations, PAF calculations perform an important function for public health in that they provide a framework for greater understanding of disease etiology in populations, and stimulate the public health community to evaluate the feasibility of primary prevention strategies [69].

There are several additional limitations to the present analysis. *BRCA1* carrier status was determined for only a small sample of women in the CBCS [70]. It is possible that some basal-like cases were *BRCA1* mutation carriers, but this number is likely to be very small given the

low frequency of *BRCA1* carriers in the CBCS [70] and other population-based studies [71]. Another caveat is that IHC surrogates were used to subtype CBCS cases since fresh tumor samples were unavailable to perform gene expression profiling. The IHC surrogates have been validated in another study population, showing excellent agreement with gene expression profiling [10], and they have been utilized in other studies to detect the presence of the five “intrinsic” breast cancer subtypes [67,72–74]. Although tumor blocks tended to be available from cases with larger tumors, the case-only subtype comparisons did not differ when we adjusted for stage at diagnosis. Sample size was small for many of the subsets of interest, and our results need to be replicated in other population-based studies. Our study was limited largely to African-American and white women, and studies of the epidemiology of basal-like breast cancer among Hispanic women and other minority groups is an important area for future investigation.

Interventions to reduce the risk of basal-like breast cancer have strong prior justification. In a summary of existing data on breast cancer among younger African-American women, Bernstein et al. [43] targeted increasing breastfeeding, losing weight, and increasing physical activity as the most effective ways of reducing disease risk. Our study adds further support for these recommendations. The benefits of breastfeeding for mother and child are well-documented [75]. The Centers for Disease Control and Prevention Goals for Healthy People 2010 lists a target of 75% of mothers breastfeeding in the immediate postpartum period, with at least 50% continuing to breastfeed for 6 months [76]. As observed in the CBCS, the prevalence of breastfeeding is reported to be lower among younger African-American women compared to white women [42,43,76]. Lack of information about benefits, restrictions surrounding employment, and social pressures limit breastfeeding [75], and maternal obesity decreases initiation as well as continuation of lactation [77]. Teenage mothers may experience particular barriers to breastfeeding. In the CBCS, the proportion of controls who reported having a child before the age of 20 was higher among African-American (45%) compared with white women (23%,  $P < 0.0001$ ). Thus, the reasons for lower prevalence of breastfeeding among younger African American women are complex, and interventions to encourage breastfeeding must operate at the level of the community, the workplace, and society at large [78].

Public health interventions aimed at avoiding over-nutrition, promoting a healthy diet, and encouraging physical activity [79] could impact the incidence of basal-like breast cancer, especially programs that target excessive weight gain. Reduction in abdominal adiposity would provide additional benefits, including reduced risk of diabetes mellitus and heart disease [28, 50]. The prevalence of obesity is increasing among pregnant women [80], leading to increased risk of hypertension and perinatal mortality [81]. A variety of barriers at the school and neighborhood level [82] may need to be overcome to promote physical activity among young girls.

Interventions to reduce risk of basal-like breast cancer would take years to have an impact, especially if early stages of carcinogenesis were targeted. Measures to improve survival for patients with basal-like breast cancer will have a more immediate impact. Increased adiposity at the time of diagnosis can confer a worse prognosis for younger breast cancer patients [83], and this poor prognosis may be especially relevant for women with basal-like disease. Timely and effective treatment is vitally important for patients with basal-like breast cancer, and a variety of new drugs are being evaluated in clinical trials [84]. However, African-American women historically suffer from reduced access to quality health care, delays in diagnosis and treatment, and low enrollment in clinical trials, and these disparities need to be addressed more effectively in the future [85–88]. Health care providers need to be aware of the possibility of a breast cancer subtype with distinct etiology and worse prognosis. Unfortunately, clinicians may overlook breast cancer among younger women when patients do not present with a

“classic” set of risk factors [35]. Determination of the sensitivity and specificity of screening mammography for basal-like breast cancer would have important implications for detection and diagnosis of breast cancer, particularly in younger women. Finally, risk assessment models for breast cancer may need to be modified to identify women at high-risk for the basal-like subtype.

## Conclusions

The “intrinsic” breast cancer subtypes, luminal A and basal-like, exhibit distinct risk factors. Basal-like breast cancer is associated with early-onset menarche, younger age at first full-term pregnancy, high parity combined with lack of breast feeding, and abdominal adiposity. In contrast to recent commentaries suggesting that basal-like breast cancer represents the “exclusive” property of a specific age and racial group by virtue of genetics [89–91], our data show that the basal-like subtype is present in younger white breast cancer patients as well as older African-American and white patients at appreciable frequencies. Furthermore, distributional differences of basal-like breast cancer by age and race appear to be largely attributable to varying distributions of the currently identified risk factors for basal-like breast cancer. Programs aimed at promoting breast-feeding and reducing abdominal adiposity would reduce the number of cases of basal-like breast cancer among all women. Such interventions would be particularly relevant for younger African-American women, among whom the prevalence of risk factors for basal-like breast cancer is high.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

The work was funded by the Specialized Program of Research Excellence (SPORE) in Breast Cancer at UNC (NIH/NCI P50-CA58223) and the Lineberger Comprehensive Cancer Center Core Grant (P30-CA16086). CMP was supported by NCI R01-CA101227, the Breast Cancer Research Foundation, and the V Foundation for Cancer Research. The authors acknowledge the technical assistance and support of the Immunohistochemistry Core Facility at UNC directed by Dr. Lynn G. Dressler and David Cowan. The authors wish to thank participants in the National Breast Cancer Coalition Advocacy Conference, April 2007, for comments on the results of this study. The authors also thank Drs. Christine Friedenreich and Giske Ursin for helpful discussions.

## References

1. Wetzels R, Holland R, van Haelst U, et al. Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast. *Am J Pathol* 1989;134:571–579. [PubMed: 2466404]
2. Perou C, Jeffrey S, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. *Proc Natl Acad Sci* 1999;96:9212–9217. [PubMed: 10430922]
3. Perou C, Sorlie T, Eisen M, et al. Molecular portraits of human breast tumours. *Nature* 2000;406:747–752. [PubMed: 10963602]
4. Sorlie T, Perou C, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci* 2001;98:10869–10874. [PubMed: 11553815]
5. Sorlie T, Wang Y, Xiao C, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. *BMC Genomics* 2006;7:127. [PubMed: 16729877]
6. Hu Z, Fan C, Oh D, et al. The molecular portraits of breast tumors are conserved across microarray platforms. *BMC Genomics* 2006;7:96. [PubMed: 16643655]
7. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci* 2003;100:8418–8423. [PubMed: 12829800]



8. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. *Breast Cancer Res* 2006;8:R34. [PubMed: 16846532]
9. Fan C, Oh D, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. *N Engl J Med* 2006;355:560–569. [PubMed: 16899776]
10. Nielsen T, Hsu F, Jensen K, et al. Immunohistochemical and clinical characteristics of the basal-like subtype of invasive breast carcinoma. *Clin Cancer Res* 2004;10:5367–5374. [PubMed: 15328174]
11. Carey L, Perou C, Livasy C, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. *J Am Med Assoc* 2006;295:2492–2502.
12. Livasy C, Perou C, Karaca G, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. *Hum Pathol* 2007;38:197–204. [PubMed: 17234468]
13. Newman B, Moorman PG, Millikan R, et al. The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. *Breast Cancer Res Treat* 1995;35:51–60. [PubMed: 7612904]
14. Millikan RC, Pittman GS, Newman B, et al. Cigarette smoking, *N*-acetyltransferases 1 and 2 and breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 1998;7:371–378. [PubMed: 9610785]
15. Weinberg C, Sandler D. Randomized recruitment in case–control studies. *Am J Epidemiol* 1991;134:421–432. [PubMed: 1877602]
16. Millikan R, Eaton A, Worley K. HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. *Breast Cancer Res Treat* 2003;79:355–364. [PubMed: 12846420]
17. Furberg H, Newman B, Moorman P, et al. Lactation and breast cancer risk. *Int J Epidemiol* 1999;28:396–402. [PubMed: 10405840]
18. Kinney AY, Millikan RC, Lin YH. Alcohol consumption and breast cancer among black and white women in North Carolina. *Cancer Causes Control* 2000;11:345–357. [PubMed: 10843445]
19. Moorman P, Millikan R, Newman B. Oral contraceptives and breast cancer among African-American women and white women. *J Natl Med Assoc* 2001;9:329–334. [PubMed: 11560288]
20. Moorman P, Kuwabara H, Millikan R, et al. Menopausal hormones and breast cancer in a biracial population. *Am J Public Health* 2000;90:966–971. [PubMed: 10846517]
21. Dressler L, Geradts J, Burroughs M, et al. Policy guidelines for the utilization of formalin-fixed, paraffin-embedded tissue sections: the UNC SPORE experience. *Breast Cancer Res Treat* 1999;58:31–39. [PubMed: 10634516]
22. Huang W-Y, Newman B, Millikan R. Hormone-related factors and risk of breast cancer by estrogen receptor and progesterone receptor status. *Am J Epidemiol* 2000a;151:703–714. [PubMed: 10752798]
23. Barnes N, Boland G, Davenport A. Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ. *Br J Surg* 2005;92:429–434. [PubMed: 15736216]
24. National Heart, Lung, and Blood Institute (NHLBI) Expert Panel on the identification, evaluation, and treatment of overweight and obesity in adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. *Obes Res* 1998;6 (suppl 2):51S–209S. [PubMed: 9813653]
25. Begg C, Zhang Z-F. Statistical analysis of molecular epidemiology studies employing case-series. *Cancer Epidemiol Biomarkers Prev* 1994;3:173–175. [PubMed: 8049640]
26. Greenland S, Pearl J, Robins J. Causal diagrams for epidemiologic research. *Epidemiology* 1999;10:37–48. [PubMed: 9888278]
27. Vineis P, Kriebel D. Causal models in epidemiology: past inheritance and genetic future. *Environ Health Glob Access Sci Source* 2006;5:21.
28. Harvie M, Hooper L, Howell A. Central obesity and breast cancer risk: a systematic review. *Obes Rev* 2003;4:157–173. [PubMed: 12916817]
29. Lahmann P, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer* 2004;111:762–771. [PubMed: 15252848]
30. Bruzzi P, Green S, Byar D, et al. Estimating the population attributable risk for multiple risk factors using case–control data. *Am J Epidemiol* 1985;122:904–914. [PubMed: 4050778]

31. Rockhill B, Weinberg CR, Newman B. Population attributable fraction estimation for established breast cancer risk factors: considering the issues of high prevalence and unmodifiability. *Am J Epidemiol* 1998a;147:826–833. [PubMed: 9583712]
32. Anderson W, Jatoi I, Devesa S. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. *Breast Cancer Res Treat* 2005;90:127–137. [PubMed: 15803359]
33. Bernards R, Weinberg R. A progression puzzle. *Nature* 2002;418:823. [PubMed: 12192390]
34. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. *CA Cancer J Clin* 2006;56:168–183. [PubMed: 16737949]
35. Swanson G, Haslam S, Azzouz F. Breast cancer among young African-American women. *Cancer* 2003;97(1 Suppl):273–279. [PubMed: 12491491]
36. Clarke C, West D, Edwards B, et al. Existing data on breast cancer in African-American women: what we know and what we need to know. *Cancer* 2003;97(1 Suppl):211–221. [PubMed: 12491484]
37. Amend K, Hicks D, Ambrosone C. Breast cancer in African-American women: differences in tumor biology from European-American women. *Cancer Res* 2006;66:8327–8330. [PubMed: 16951137]
38. Mayberry R, Stoddard-Wright C. Breast cancer risk factors among black women and white women: similarities and differences. *Am J Epidemiol* 1994;136:1445–1456. [PubMed: 1288274]
39. Palmer J, Wise L, Horton N, et al. Dual effect of parity on breast cancer risk in African-American women. *J Natl Cancer Inst* 2003;95:478–483. [PubMed: 12644541]
40. Althuis M, Brogan D, Coates R, et al. Breast cancers among very young premenopausal women. *Cancer Causes Control* 2003;14:151–160. [PubMed: 12749720]
41. Hall I, Moorman P, Millikan R, et al. Comparative analysis of breast cancer risk factors among African-American women and white women. *Am J Epidemiol* 2005;161:40–51. [PubMed: 15615914]
42. Ursin G, Bernstein L, Wang Y, et al. Reproductive factors and risk of breast carcinoma in a study of white and African-American women. *Cancer* 2004;101:353–362. [PubMed: 15241834]
43. Bernstein L, Teal C, Joslyn S, et al. Ethnicity-related variation in breast cancer risk factors. *Cancer* 2003;97(1 Suppl):222–229. [PubMed: 12491485]
44. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. *Lancet* 2002;360:187–195. [PubMed: 12133652]
45. Lipworth L, Bailey L, Trichopoulos D. History of breast-feeding in relation to breast cancer risk: a review of the epidemiologic literature. *J Natl Cancer Inst* 2000;92:302–312. [PubMed: 10675379]
46. Symmans W, Fitterman D, Anderson S. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. *Endor Relat Cancer* 2005;12:1059–1069.
47. Tischowitz M, Foulkes W. The basal phenotype of BRCA1-related breast cancer: past, present and future. *Cell Cycle* 2006;5:963–967. [PubMed: 16687925]
48. Jernstrom H, Lubinski J, Lynch H, et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 2004;96:1094–1098. [PubMed: 15265971]
49. Russo J, Balogh G, Heulings R, et al. Molecular basis of pregnancy-induced breast cancer protection. *Eur J Cancer Prev* 2006;15:306–342. [PubMed: 16835503]
50. Friedenreich C. Review of anthropometric factors and breast cancer risk. *Eur J Cancer Prev* 2001;10:15–32. [PubMed: 11263588]
51. Perry A, Applegate E, Jackson M, et al. Racial differences in visceral adipose tissue but not anthropometric markers of health-related variables. *J Appl Physiol* 2000;89:636–643. [PubMed: 10926648]
52. Lovejoy J, de la Bretonne J, Klemperer M, et al. Abdominal fat distribution and metabolic risk factors: effects of race. *Metabolism* 1996;45:1119–1124. [PubMed: 8781299]
53. Garofalo C, Koda M, Cascio S, et al. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. *Clin Cancer Res* 2006;12:1447–1453. [PubMed: 16533767]

54. Friedenreich C, Courneya K, Bryant H. Case-control study of anthropometric measures and breast cancer risk. *Int J Cancer* 2002;99:445–452. [PubMed: 11992416]
55. Eng S, Gammon M, Terry M, et al. Body size changes in relation to postmenopausal breast cancer among women on Long Island, New York. *Am J Epidemiol* 2005;162:229–237. [PubMed: 15987723]
56. Slattery M, Sweeney C, Edwards S, et al. Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. *Breast Cancer Res Treat* 2007;102:85–101. [PubMed: 17080310]
57. Kushi L, Potter J, Bostick R, et al. Dietary fat and risk of breast cancer according to hormone receptor status. *Cancer Epidemiol Biomarkers Prev* 1995;4:11–19. [PubMed: 7894319]
58. Cho E, Chen W, Hunter D, et al. Red meat intake and risk of breast cancer among premenopausal women. *Arch Intern Med* 2006;166:2253–2259. [PubMed: 17101944]
59. Colditz G, Rosner G, Chen W, et al. Risk factors for breast cancer according to estrogen and progesterone receptor status. *J Natl Cancer Inst* 2005;96:218–228. [PubMed: 14759989]
60. Li C, Malone K, Daling J. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. *Cancer Epidemiol Biomarkers Prev* 2002;11:601–607. [PubMed: 12101106]
61. Chlebowski R, Chen Z, Anderson G, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. *J Natl Cancer Inst* 2005;97:439–448. [PubMed: 15770008]
62. Dallal C, Sullivan-Halley J, Ross R, et al. Long-term recreational physical activity and risk of invasive and in situ breast cancer. *Arch Intern Med* 2007;167:408–415. [PubMed: 17325304]
63. Althuis M, Fergenbaum J, Garcia-Closas M, et al. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. *Cancer Epidemiol Biomarkers Prev* 2004;13:1558–1568. [PubMed: 15466970]
64. Ma H, Bernstein L, Pike M, et al. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. *Breast Cancer Res* 2006;8:R43. [PubMed: 16859501]
65. Huang W-Y, Newman B, Millikan R, et al. Risk of breast cancer according to the status of HER-2/neu oncogene amplification. *Cancer Epidemiol Biomarkers Prev* 2000b;9:65–71. [PubMed: 10667465]
66. Bauer K, Brown M, Cress R, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. *Cancer* 2007;109:1721–1728. [PubMed: 17387718]
67. Yang X, Sherman M, Rimm D, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. *Cancer Epidemiol Biomarkers Prev* 2007;16:439–443. [PubMed: 17372238]
68. Moorman PG, Newman B, Millikan RC, et al. Participation rates in a case-control study: the impact of age, race, and race of interviewer. *Ann Epidemiol* 1999;9:188–195. [PubMed: 10192651]
69. Rockhill B, Newman B, Weinberg C. Uses and abuses of population attributable fraction. *Am J Public Health* 1998b;88:15–19. [PubMed: 9584027]
70. Newman B, Mu H, Butler LM, et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. *J Am Med Assoc* 1998;279:915–921.
71. Malone K, Daling J, Doody D, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. *Cancer Res* 2006;66:8297–8308. [PubMed: 16912212]
72. Potemski P, Kusinska R, Watala C, et al. Prognostic relevance of basal cytokeratins expression in operable breast cancer. *Oncology* 2005;69:478–485. [PubMed: 16410686]
73. El-Rehim A, Ball G, Pinder S, et al. High-throughput protein expression analysis using tissue microarray technology of a large, well-characterized series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. *Int J Cancer* 2005;116:340–350. [PubMed: 15818618]
74. Kim M-J, Ro J, Ahn S-H, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. *Hum Pathol* 2006;37:1217–1226. [PubMed: 16938528]

75. Labbok M, Clark D, Goldman A. Breastfeeding: maintaining an irreplaceable immunological resource. *Nat Rev Immunol* 2004;4:565–572. [PubMed: 15229475]
76. Centers for Disease Control and Prevention. Healthy People 2010. 2006. <http://www.healthypeople.gov/Documents/HTML/Volume2>
77. Rasmussen K. Association of maternal obesity before conception with poor lactation performance. *Annu Rev Nutr* 2007;27:10.1146/annurev.nutr.27.061406.093738 [PubMed: 217341160]
78. Bentley M, Dee D, Jensen J. Breastfeeding among low income, African-American women: power, beliefs and decision-making. *J Nutr* 2003;133:305S–309S. [PubMed: 12514315]
79. Kushi L, Byers T, Doyle C, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. *CA Cancer J Clin* 2006;56:254–281. [PubMed: 17005596]
80. Ray J, Nisenbaum R, Singh G, et al. Trends in obesity in pregnancy. *Epidemiology* 2007;18:280–281. [PubMed: 17301710]
81. Bodnar L, Catov J, Klebanoff M, et al. Prepregnancy body mass index and the occurrence of severe hypertensive disorders of pregnancy. *Epidemiology* 2007;18:234–239. [PubMed: 17237733]
82. Evenson K, Scott M, Cohen D, et al. Girls' perception of neighborhood factors on physical activity, sedentary behavior, and BMI. *Obesity* 2007;15:430–445. [PubMed: 17299117]
83. Abrahamson P, Gammon M, Lund M, et al. General and abdominal obesity and survival among young women with breast cancer. *Cancer Epidemiol Biomarkers Prev* 2006;15:1871–1877. [PubMed: 17035393]
84. Mullan P, Millikan R. Molecular subtyping of breast cancer: opportunities for new therapeutic approaches. *Cell Mol Life Sci.* 2007(in press)
85. Blackman D, Masi C. Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes? *J Clin Oncol* 2006;24:2170–2178. [PubMed: 16682736]
86. Newman L, Griffith K, Jatoi I, et al. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. *J Clin Oncol* 2006;24:1342–1349. [PubMed: 16549828]
87. Gorin S, Heck J, Cheng B, et al. Delays in breast cancer diagnosis and treatment by racial/ethnic group. *Arch Intern Med* 2006;166:2244–2252. [PubMed: 17101943]
88. Gwyn K, Bondy M, Cohen D, et al. Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinoma. *Cancer* 2004;100:1595–1604. [PubMed: 15073845]
89. Couzin J. Probing the roots of race and cancer. *Science* 2007;315:592–594. [PubMed: 17272699]
90. Grady D. Racial component is found in lethal breast cancer. *New York Times*, June 2006;7:2006.
91. Johnson C (2006) Breast cancer worse for young black women. *AP News Service*, June 6, 2006, AP stories

**Table 1**

Distribution of breast cancer subtypes according to race and menopausal status

Breast cancer subtype	African-American premenopausal <i>N</i> <sup>a</sup> (%) <sup>b</sup>	African-American postmenopausal <i>N</i> (%)	White premenopausal <i>N</i> (%)	White postmenopausal <i>N</i> (%)
Luminal A <i>N</i> = 796	108 (41.4)	179 (56.3)	216 (57.4)	293 (66.5)
Basal-like <i>N</i> = 225	70 (27.2)	52 (16.0)	54 (14.5)	49 (9.3)
HER2+/ER- <i>N</i> = 116	22 (8.4)	26 (7.7)	24 (5.6)	44 (6.0)
Luminal B <i>N</i> = 137	19 (7.3)	26 (8.7)	46 (12.4)	46 (10.7)
Unclassified <i>N</i> = 150	41 (15.7)	38 (11.3)	38 (10.1)	33 (7.5)
Total: 1,424 <i>P</i> <sup>c</sup> <0.0001	260 (100)	321 (100)	378 (100)	465 (100)

<sup>a</sup>Numbers in table are observed numbers (not adjusted for sampling probabilities)

<sup>b</sup>Percentages in table are adjusted for sampling probabilities

<sup>c</sup>Chi square test adjusted for sampling probabilities



**Table 2**  
Case-only ORs comparing basal-like, HER2+/ER-, luminal B and unclassified to luminal A breast cancer

Risk factor	Luminal A		Basal-like		HER2+/ER-		Luminal B		Unclassified	
	N	N	N	OR (95% CI)	N	OR (95% CI)	N	OR (95% CI)	N	OR (95% CI)
Age <sup>d</sup>										
≥60	259	35	Referent	Referent	27	Referent	37	Referent	37	Referent
50-59	181	46	1.8 (1.1-2.8)	1.5 (0.8-2.6)	29	1.5 (0.8-2.6)	28	1.1 (0.6-1.9)	25	0.9 (0.5-1.6)
40-49	267	89	2.6 (1.7-3.9)	1.4 (0.8-2.4)	39	2.6 (1.7-3.9)	50	1.3 (0.8-2.1)	59	1.6 (1.0-2.5)
<40	89	55	4.5 (2.7-7.3)	2.3 (1.2-4.2)	21	4.5 (2.7-7.3)	22	1.7 (1.0-3.1)	29	2.2 (1.3-3.9)
Trend test		<i>P</i> < 0.0001			<i>P</i> = 0.02		<i>P</i> = 0.06		<i>P</i> = 0.001	
Race <sup>b</sup>										
White	509	103	Referent	Referent	68	Referent	92	Referent	71	Referent
African-American	287	122	2.1 (1.6-2.9)	1.3 (0.8-1.9)	48	2.1 (1.6-2.9)	45	0.9 (0.6-1.3)	79	2.0 (1.4-2.8)
Menopausal status <sup>c</sup>										
Postmenopausal	472	101	Referent	Referent	70	Referent	72	Referent	71	Referent
Premenopausal	324	124	0.8 (0.5-1.3)	0.4 (0.3-0.8)	46	0.8 (0.5-1.3)	65	1.0 (0.6-1.7)	79	1.1 (0.6-1.9)
Family history <sup>c</sup>										
No	640	186	Referent	Referent	95	Referent	111	Referent	119	Referent
Yes	130	36	1.0 (0.7-1.5)	0.9 (0.5-1.6)	17	1.0 (0.7-1.5)	25	1.1 (0.7-1.8)	24	1.0 (0.6-1.7)
Age at menarche <sup>c</sup>										
≥13	406	100	Referent	Referent	58	Referent	71	Referent	61	Referent
<13	389	125	1.3 (0.9-1.7)	1.0 (0.7-1.5)	58	1.3 (0.9-1.7)	66	0.9 (0.7-1.4)	88	1.5 (1.0-2.1)
Parity <sup>c</sup>										
Nulliparous	132	26	Referent	Referent	23	Referent	19	Referent	19	Referent
1-2 children	381	117	1.6 (1.0-2.7)	0.8 (0.5-1.3)	51	1.6 (1.0-2.7)	73	1.3 (0.8-2.3)	70	1.3 (0.8-2.3)
≥3	283	82	1.7 (1.0-2.9)	1.0 (0.5-1.7)	42	1.7 (1.0-2.9)	45	1.3 (0.7-2.3)	61	1.7 (1.0-3.0)
Age at first full-term pregnancy (AFFTP) <sup>c</sup>										
Nulliparous	132	26	Referent	Referent	23	Referent	19	Referent	19	Referent
<26	477	159	1.9 (1.2-3.0)	0.8 (0.5-1.5)	70	1.9 (1.2-3.0)	77	1.2 (0.7-2.1)	96	1.5 (0.9-2.5)
≥26	184	39	1.2 (0.7-2.1)	0.7 (0.4-1.3)	22	1.2 (0.7-2.1)	41	1.6 (0.9-2.8)	35	1.5 (0.8-2.7)
Lifetime duration lactation <sup>c</sup>										
Never	500	158	Referent	Referent	76	Referent	87	Referent	100	Referent
>0-3 months	92	27	1.1 (0.7-1.9)	1.1 (0.6-2.0)	14	1.1 (0.7-1.9)	17	1.1 (0.6-1.9)	11	0.7 (0.4-1.4)
4+	204	40	0.7 (0.5-1.1)	0.9 (0.6-1.5)	26	0.7 (0.5-1.1)	33	1.0 (0.6-1.5)	39	1.1 (0.7-1.7)
Alcohol use <sup>c</sup>										
Never	240	70	Referent	Referent	35	Referent	30	Referent	62	Referent
Ever	556	154	0.9 (0.6-1.2)	1.0 (0.6-1.5)	81	0.9 (0.6-1.2)	107	1.4 (0.9-2.2)	88	0.6 (0.4-0.9)
Smoking duration <sup>c</sup>										
Never smoker	408	126	Referent	Referent	66	Referent	66	Referent	94	Referent
<10 years	94	31	0.9 (0.6-1.5)	0.9 (0.5-1.6)	14	0.9 (0.6-1.5)	18	1.1 (0.6-1.9)	17	0.8 (0.4-1.3)
11-19	90	31	1.1 (0.7-1.7)	0.7 (0.4-1.4)	11	1.1 (0.7-1.7)	15	1.0 (0.5-1.8)	10	0.5 (0.2-1.0)
≥20	201	37	0.7 (0.5-1.1)	0.8 (0.5-1.4)	25	0.7 (0.5-1.1)	37	1.2 (0.8-1.9)	29	0.7 (0.5-1.2)
Oral contraceptive use <sup>c</sup>										
Never	286	66	Referent	Referent	35	Referent	44	Referent	50	Referent
Ever	507	158	0.9 (0.6-1.3)	1.1 (0.6-1.7)	80	0.9 (0.6-1.3)	93	0.9 (0.6-1.5)	99	0.8 (0.5-1.3)
Hormone replacement therapy (postmenopausal women only) <sup>c</sup>										
Never	247	60	Referent	Referent	32	Referent	29	Referent	35	Referent
Ever	225	41	0.8 (0.5-1.3)	1.2 (0.7-2.1)	38	0.8 (0.5-1.3)	43	1.6 (0.9-2.8)	36	1.4 (0.8-2.4)
BMI (kg/m <sup>2</sup> ) <sup>c</sup>										
Overall	288	64	Referent	Referent	41	Referent	59	Referent	60	Referent
<25	208	66	1.4 (1.0-2.2)	1.2 (0.8-2.0)	36	1.4 (1.0-2.2)	39	1.0 (0.6-1.5)	26	0.6 (0.3-0.9)
25-29										

Risk factor	Luminal A		Basal-like		HER2+/ER-		Luminal B		Unclassified	
	N	N	N	OR (95% CI)	N	OR (95% CI)	N	OR (95% CI)	N	OR (95% CI)
Premenopausal	277	88	1.3 (0.8-1.9)	36	0.9 (0.5-1.5)	38	0.7 (0.4-1.1)	59	0.8 (0.5-1.2)	
<25	138	34	Referent	20	Referent	29	Referent	31	Referent	
25-29	75	35	1.7 (1.0-3.1)	13	1.1 (0.5-2.3)	22	1.4 (0.8-2.7)	13	0.7 (0.3-1.5)	
≥30	105	50	1.6 (0.9-2.7)	12	0.6 (0.3-1.5)	14	0.7 (0.3-1.4)	32	1.1 (0.6-2.0)	
Postmenopausal	150	30	Referent	21	Referent	30	Referent	29	Referent	
<25	133	31	1.2 (0.7-3.0)	23	1.3 (0.7-2.5)	17	0.6 (0.3-1.2)	13	0.5 (0.2-0.9)	
25-29	172	38	1.0 (0.5-1.7)	24	1.1 (0.6-2.2)	24	0.7 (0.4-1.3)	27	0.6 (0.3-1.1)	
≥30										
WHR <sup>c</sup>										
Overall	210	40	Referent	38	Referent	53	Referent	36	Referent	
<0.77	268	89	2.0 (1.3-3.0)	42	0.9 (0.5-1.5)	38	0.6 (0.4-1.0)	40	0.9 (0.5-1.5)	
0.77-0.83	306	91	1.7 (1.1-2.8)	35	0.6 (0.4-1.1)	44	0.6 (0.4-1.0)	71	1.3 (0.8-2.1)	
≥0.84										
Premenopausal	122	25	Referent	16	Referent	29	Referent	25	Referent	
<0.77	113	56	2.3 (1.3-4.1)	18	1.2 (0.6-2.6)	18	0.7 (0.4-1.3)	23	1.0 (0.5-1.8)	
0.77-0.83	86	41	1.9 (1.0-3.6)	11	0.9 (0.4-2.2)	17	0.9 (0.4-1.8)	28	1.4 (0.7-2.7)	
≥0.84										
Postmenopausal	88	15	Referent	22	Referent	24	Referent	11	Referent	
<0.77	155	33	1.4 (0.7-2.8)	24	0.7 (0.4-1.4)	20	0.5 (0.3-1.0)	17	0.8 (0.4-1.9)	
0.77-0.83	220	50	1.4 (0.7-2.7)	24	0.5 (0.3-1.0)	17	0.5 (0.2-0.9)	43	1.3 (0.6-2.7)	
≥0.84										

<sup>a</sup> Adjusted for race

<sup>b</sup> Adjusted for age

<sup>c</sup> Adjusted for age and race

**Table 3**  
Case-control odds ratios comparing luminal A cases versus controls and basal-like cases versus controls

Risk factor	Controls		Luminal A		Basal-like		OR (95% CI)
	N		N		N		
Age at menarche <sup>c</sup>							
≥13	1,072		406		100		Referent
<13	942		389		125		1.4 (1.1-1.9)
Parity <sup>b</sup>							
Nulliparous	230		132		26		Referent
1 child	343		122		38		1.7 (0.9-3.0)
2	670		259		79		1.8 (1.1-3.1)
≥3	779		283		82		1.9 (1.1-3.3)
				<i>P</i> = 0.07			<i>P</i> = 0.04
Trend test							
Age at first full-term pregnancy <sup>b</sup>							
Nulliparous	230		132		26		Referent
<26	1,354		477		159		1.9 (1.2-3.2)
≥26	435		184		39		1.5 (0.8-2.8)
Breastfeeding <sup>c</sup>							
Never	1,223		500		158		Referent
Ever	799		296		67		0.7 (0.5-1.0)
Lifetime duration lactation <sup>c</sup>							
Never	1,223		500		158		Referent
>0 to 3 months	280		92		27		0.9 (0.6-1.4)
≥4	516		204		40		0.7 (0.4-0.9)
Trend test				<i>P</i> = 0.26			<i>P</i> = 0.03
Number of children breastfed <sup>c</sup>							
Never	1,223		500		158		Referent
1	384		121		35		0.8 (0.6-1.2)
≥2	415		175		32		0.6 (0.4-0.9)
Trend test				<i>P</i> = 0.33			
Ave. number months breastfeeding per child <sup>c</sup>							
Never	1,223		500		158		Referent
0-3.9	480		172		42		0.8 (0.6-1.2)
≥4	316		124		25		0.6 (0.4-0.9)
Trend test				<i>P</i> = 0.20			
Lactation suppressant use <sup>c</sup>							
Never	1,033		447		102		Referent
Ever	989		349		123		1.5 (1.1-2.0)
Parity and lactation <sup>c</sup>							
Nulliparous	230		132		26		Referent
1-2, never	625		232		81		1.8 (1.1-3.0)
1-2, ever	388		149		36		1.1 (0.6-2.0)
≥3, never	368		136		51		1.9 (1.1-3.3)
≥3, ever	411		147		31		1.3 (0.7-2.3)
Parity and AFFTP <sup>c</sup>							
Nulliparous	230		132		26		Referent
1-2, <26	653		221		82		1.7 (1.0-2.8)
1-2, ≥26+	360		160		34		1.2 (0.7-2.2)
≥3, <26	701		256		77		1.6 (1.0-2.8)
≥3, ≥26+	75		24		5		1.2 (0.4-3.5)
BMI (kg/m <sup>2</sup> ) <sup>d</sup>							
Overall							
<25	615		288		64		Referent
25-29	609		208		66		1.0 (0.7-1.5)

Risk factor	Controls		Luminal A		Basal-like	
	N		N	OR (95% CI)	N	OR (95% CI)
≥30	751		277	0.8 (0.6–1.0)	88	0.8 (0.6–1.2)
Trend test						
Premenopausal						
<25	292		138	Referent	34	Referent
25–29	233		75	0.7 (0.5–1.0)	35	1.1 (0.7–1.9)
≥30	318		105	0.7 (0.5–1.0)	50	1.0 (0.6–1.8)
Trend test						
Postmenopausal						
<25	323		150	Referent	30	Referent
25–29	376		133	0.8 (0.6–1.0)	31	0.8 (0.5–1.4)
≥30	433		172	0.8 (0.6–1.1)	38	0.6 (0.3–1.1)
Trend test						
WHR <sup>e</sup>						
Overall	615		210	Referent	40	Referent
<0.77	646		268	1.3 (1.1–1.7)	89	2.3 (1.5–3.5)
0.77–0.83	732		306	1.5 (1.1–1.9)	91	2.3 (1.4–3.6)
≥0.84						
Trend test						
Premenopausal						
<0.77	324		122	Referent	25	Referent
0.77–0.83	277		113	1.3 (0.9–1.8)	56	2.6 (1.5–4.5)
≥0.84	253		86	1.2 (0.8–1.8)	41	1.8 (1.0–3.4)
Trend test						
Postmenopausal						
<0.77	291		88	Referent	15	Referent
0.77–0.83	369		155	1.5 (1.1–2.1)	33	1.8 (0.9–3.6)
≥0.84	479		220	1.8 (1.3–2.6)	50	2.7 (1.3–5.4)
Trend test						

<sup>a</sup> Adjusted for offsets, age (continuous), race (African-American, white), menopausal status (pre-, postmenopausal), family history (yes, no), alcohol use (ever, never), smoking duration (never, ≤10, 11–20, >20 years), oral contraceptive use (ever, never), parity (nulliparous, 1–2, 3+), breastfeeding (ever, never)

<sup>b</sup> Adjusted for offsets, age, race, menopausal status, family history, alcohol use, smoking duration, oral contraceptive use, age at menarche (<13, 13+, breastfeeding)

<sup>c</sup> Adjusted for offsets, age, race, menopausal status, family history, alcohol use, smoking duration, oral contraceptive use, age at menarche

<sup>d</sup> Adjusted for offsets, age, race, menopausal status (overall analysis), family history, alcohol use, smoking duration, oral contraceptive use, age at menarche, parity breastfeeding

<sup>e</sup> Adjusted for offsets, age, race, menopausal status (overall analysis), family history, alcohol use, smoking duration, oral contraceptive use, age at menarche, parity breastfeeding and BMI (continuous)

**Table 4**

Distributions of selected basal-like risk factors among controls according to race and menopausal status

Characteristic <sup>a</sup>	African-American premenopausal (%)	African-American postmenopausal (%)	White premenopausal (%)	White postmenopausal (%)
Age at menarche <13 <i>P</i> <sup>b</sup> = 0.03	54	36	45	46
Never breastfed <i>P</i> = 0.0001	76	66	61	61
Lifetime duration breastfeeding ≥4 months <i>P</i> < 0.0001	13	27	29	21
Parous women ≥2 children breastfed <i>P</i> < 0.0001	13	24	33	19
≥4 months breastfeeding per child <i>P</i> < 0.0001	10	18	34	12

<sup>a</sup>Percentages in table are adjusted for sampling probabilities

<sup>b</sup>Chi square test adjusted for sampling probabilities



**Table 5**

Distributions of selected basal-like risk factors in African-American and white controls under age 40 and aged 40–49

Characteristic <sup>a</sup>	African-American age <40 (%)	White age <40 (%)	African-American age 40–49 (%)	White age 40–49 (%)
Parity ≥3	24 <i>P</i> <sup>b</sup> = 0.45	13	41 <i>P</i> = 0.0001	19
Never breastfed	82 <i>P</i> = 0.01	61	75 <i>P</i> = 0.0003	61
Parity ≥3 and never breastfed	18 <i>P</i> = 0.002	5	30 <i>P</i> < 0.0001	7
Lactation suppressants, ever use	34 <i>P</i> = 0.06	19	61 <i>P</i> = 0.0003	42
Parous women: AFFTP <26	78 <i>P</i> = 0.04	59	86 <i>P</i> < 0.0001	61
Parous women ≥2 children breastfed	9 <i>P</i> < 0.0001	37	14 <i>P</i> < 0.0001	27
≥4 months breastfeeding per child	9 <i>P</i> < 0.0001	39	10 <i>P</i> < 0.0001	26
WHR ≥0.77	61 <i>P</i> = 0.31	46	80 <i>P</i> < 0.0001	55

<sup>a</sup>Percentages in table are adjusted for sampling probabilities

<sup>b</sup>Chi square test comparing African-American and white controls in each age group, adjusted for sampling probabilities